Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Grosso

Showing results (91-100 of 96) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 96 results.
Cancer Research|December 22, 2011
Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escapeSeng-Ryong Woo, Meghan E Turnis, Monica V Goldberg, et al.
JAMA Oncology|July 26, 2019
Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non-Small Cell Lung Cancer Treated With NivolumabSuzanne L Topalian, F Stephen Hodi, Julie R Brahmer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 9, 2016
Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib StudyAlexander M Lesokhin, Stephen M Ansell, Philippe Armand, et al.
Cancer Letters|May 17, 2016
CDKN2A and BAP1 germline mutations predispose to melanoma and mesotheliomaM Betti, A Aspesi, A Biasi, et al.
Nature Materials|December 19, 2022
Non-volatile electric-field control of inversion symmetryLucas Caretta, Yu-Tsun Shao, Jia Yu, et al.
The New England Journal of Medicine|June 5, 2012
Safety and activity of anti-PD-L1 antibody in patients with advanced cancerJulie R Brahmer, Scott S Tykodi, Laura Q M Chow, et al.
Pageof 10

Showing results (91-100 of 96) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 96 results.
Cancer Research|December 22, 2011
Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escapeSeng-Ryong Woo, Meghan E Turnis, Monica V Goldberg, et al.
JAMA Oncology|July 26, 2019
Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non-Small Cell Lung Cancer Treated With NivolumabSuzanne L Topalian, F Stephen Hodi, Julie R Brahmer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 9, 2016
Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib StudyAlexander M Lesokhin, Stephen M Ansell, Philippe Armand, et al.
Cancer Letters|May 17, 2016
CDKN2A and BAP1 germline mutations predispose to melanoma and mesotheliomaM Betti, A Aspesi, A Biasi, et al.
Nature Materials|December 19, 2022
Non-volatile electric-field control of inversion symmetryLucas Caretta, Yu-Tsun Shao, Jia Yu, et al.
The New England Journal of Medicine|June 5, 2012
Safety and activity of anti-PD-L1 antibody in patients with advanced cancerJulie R Brahmer, Scott S Tykodi, Laura Q M Chow, et al.
Pageof 10